Storia in 4 fonti

Takeda and Insilico strike AI-led drug discovery deal worth up to $600m

Collaboration underlines surge in cross-border biotech licensing agreements

Raccontata dacryptobriefing.commorningstar.comasia.nikkei.comscmp.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

asia.nikkei.comStai leggendo11 h fa

Takeda and Insilico strike AI-led drug discovery deal worth up to $600m

Collaboration underlines surge in cross-border biotech licensing agreements

originale

cryptobriefing.com14 h fa

Takeda and Insilico ink $600M AI drug discovery agreement

Takeda and Insilico Medicine sign a $600M AI drug discovery deal, adding to Insilico's growing portfolio of billion-dollar pharma partnerships in 2026.

Leggi questa versione → originale

morningstar.com12 h fa

Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

Leggi questa versione → originale

scmp.com3 h fa

China AI drug-design deals swell as US scrutiny mounts

Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.

Leggi questa versione → originale

Timeline cronologica

1. giovedì 2 luglio 2026·cryptobriefing.com
   

   Takeda and Insilico ink $600M AI drug discovery agreement

   Takeda and Insilico Medicine sign a $600M AI drug discovery deal, adding to Insilico's growing portfolio of billion-dollar pharma partnerships in 2026.

2. giovedì 2 luglio 2026·morningstar.com
   

   Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

   Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

3. giovedì 2 luglio 2026·asia.nikkei.com
   

   Takeda and Insilico strike AI-led drug discovery deal worth up to $600m

   Collaboration underlines surge in cross-border biotech licensing agreements

4. giovedì 2 luglio 2026·scmp.com
   

   China AI drug-design deals swell as US scrutiny mounts

   Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.